Pivotal Experiment Fund to accelerate Medicine by Design-funded research toward impact

Medicine by Design's $4-million Pivotal Experiment Fund aims to bridge one of the critical gaps in the “valley of death” between a research discovery and a translatable therapy.

Researchers delay onset of amyotrophic lateral sclerosis (ALS) in laboratory models

A team of researchers led by scientists at the University of Toronto has delayed the onset of amyotrophic lateral sclerosis (ALS) in mice. They are cautiously optimistic that this research, which was funded in part by a Medicine by Design 2018 New Ideas Award, combined with other clinical advances, points to a potential treatment for ALS in humans.

By |2020-04-24T16:19:27-04:00April 22nd, 2020|Categories: News|Tags: , , , |
Go to Top